(E)-tert-butyl 3-fluoro-4-phenoxybut-2-enylcarbamate | 1158976-83-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (E)-tert-butyl 3-fluoro-4-phenoxybut-2-enylcarbamate
• 英文别名: tert-butyl N-[(E)-3-fluoro-4-phenoxybut-2-enyl]carbamate
• CAS: 1158976-83-0
• 化学式: C₁₅H₂₀FNO₃
• 分子量: 281.327
• InChiKey: GLCWNRBQLBWFAD-FMIVXFBMSA-N

物化性质

• 沸点：
  406.9±45.0 °C(predicted)
• 密度：
  1.095±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-tert-butyl 3-fluoro-4-phenoxybut-2-enylcarbamate 、 盐酸 在 甲醇 作用下， 以 乙醚 为溶剂， 反应 68.0h， 以to afford (E)-3-fluoro-4-phenoxybut-2-en-1-amine hydrochloride (0.009 g, 46%) as an off-white solid的产率得到(E)-3-fluoro-4-phenoxybut-2-en-1-amine hydrochloride
  参考文献：
  名称：

  Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor

  摘要：

  本发明涉及一种新型卤代烯丙胺衍生物的制备和药用，其作为具有公式I结构的SSAO/VAP-1抑制剂，如规范中定义的那样：(I)。本发明还涉及使用本发明化合物或其药学上可接受的盐或衍生物的方法，用于治疗多种适应症，例如炎症性疾病。

  公开号：

  US08426587B2
• 作为产物：
  描述：

  Tert-butyl-3-fluoro-4-hydroxybut-2-enylcarbamate 、 苯酚 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 生成 (E)-tert-butyl 3-fluoro-4-phenoxybut-2-enylcarbamate 、 tert-butyl N-[(Z)-3-fluoro-4-phenoxybut-2-enyl]carbamate
  参考文献：
  名称：

  The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)

  摘要：

  A new class of 3-fluoroallyl amine-based SSAO/VAP-1 inhibitors is reported. These compounds have excellent selectivity over diamine oxidase, MAO-A and MAO-B. Synthesis and SAR studies leading to compound 28 (PXS-4159A) are reported. The pharmacokinetic profile of 28 in the rat, together with activity in a murine model of lung inflammation are also disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.111

文献信息

• HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR
  申请人：McDonald Ian A.

  公开号：US20100298330A1

  公开（公告）日：2010-11-25

  The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.

  本发明涉及一种具有I式结构的新型卤代烯丙胺衍生物的制备和药物应用，所述衍生物可作为SSAO/VAP-1抑制剂，I式结构如规范中定义。本发明还涉及使用本发明化合物或其药学上可接受的盐或衍生物的方法，用于治疗多种适应症，例如炎症性疾病。
• US8426587B2
  申请人：——

  公开号：US8426587B2

  公开（公告）日：2013-04-23
• [EN] HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR<br/>[FR] INHIBITEURS DE SSAO/VAP-1 DE TYPE HALOALLYLAMINES ET LEURS UTILISATIONS
  申请人：PHARMAXIS LTD

  公开号：WO2009066152A2

  公开（公告）日：2009-05-28

  The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
• The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)
  作者：Jonathan S. Foot、Mandar Deodhar、Craig I. Turner、Ping Yin、Ellen M. van Dam、Diego G. Silva、Aldo Olivieri、Andrew Holt、Ian A. McDonald

  DOI：10.1016/j.bmcl.2012.04.111

  日期：2012.6

  A new class of 3-fluoroallyl amine-based SSAO/VAP-1 inhibitors is reported. These compounds have excellent selectivity over diamine oxidase, MAO-A and MAO-B. Synthesis and SAR studies leading to compound 28 (PXS-4159A) are reported. The pharmacokinetic profile of 28 in the rat, together with activity in a murine model of lung inflammation are also disclosed. (C) 2012 Elsevier Ltd. All rights reserved.
• Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
  申请人：McDonald Ian A.

  公开号：US08426587B2

  公开（公告）日：2013-04-23

  The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.

  本发明涉及一种新型卤代烯丙胺衍生物的制备和药用，其作为具有公式I结构的SSAO/VAP-1抑制剂，如规范中定义的那样：(I)。本发明还涉及使用本发明化合物或其药学上可接受的盐或衍生物的方法，用于治疗多种适应症，例如炎症性疾病。